Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Temporarily unavailable
This product is listed in the catalog, but it is not currently available for ordering. Pricing, specifications, and support details remain visible while launch availability is being finalized.
Free shipping on orders over $150
Research Supplies
Need bacteriostatic water, syringes, or an alcohol prep kit? Email us — we can bundle reconstitution supplies with your order.
Ask about a research kit →Need the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
Tesamorelin binds pituitary GHRH receptors to stimulate pulsatile GH release and downstream IGF-1 elevation. Its trans-3-hexenoic acid N-terminal modification confers DPP-IV resistance, extending the functional exposure window beyond native GHRH. In Phase III trials, this translates to sustained trunk fat mass reduction measurable by DEXA.
Compound profile
Product definition
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Tesamorelin (trade name Egrifta) is a synthetic GHRH analog consisting of the full 44-amino-acid native GHRH sequence with a trans-3-hexenoic acid group attached to the N-terminus. This modification provides resistance to dipeptidyl peptidase IV (DPP-IV) degradation — the primary cleavage mechanism for native GHRH — without altering receptor binding or downstream GH signaling. The compound received FDA approval in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Phase III pharmacokinetic studies documented dose-dependent GH and IGF-1 elevation, with trunk fat mass reductions of approximately 18% versus placebo at 26 weeks of treatment in the ENCORE and TE/ANS/0049 trials. This clinical dataset is the most rigorous pharmacokinetic and pharmacodynamic characterization of any GHRH analog published for human subjects, making tesamorelin a reference anchor for GH-axis metabolic research.
Research audience
Tesamorelin is used by researchers in GH axis pharmacology, visceral adiposity biology, metabolic syndrome, and GH secretagogue research. It is particularly valuable for protocols requiring a GHRH analog with validated clinical pharmacokinetic data and documented metabolic end-point effects.
Research context
Tesamorelin was developed by Theratechnologies Inc. using trans-3-hexenoic acid conjugation technology to address the DPP-IV cleavage liability of native GHRH. The clinical development program focused on HIV-associated lipodystrophy — a metabolic complication of antiretroviral therapy characterized by excess visceral fat accumulation and GH deficiency — where sustained GH/IGF-1 stimulation was hypothesized to reverse the adipose redistribution. The Phase III ENCORE and TE/ANS/0049 trials enrolled adults with HIV-associated lipodystrophy and documented statistically significant trunk fat mass reduction, IGF-1 normalization, and improvement in lipid parameters versus placebo. This dataset, combined with the Phase I pharmacokinetic characterization, makes tesamorelin the only GHRH analog with a complete Phase III human dataset in the open literature. In preclinical and translational research settings, tesamorelin is studied as a pharmacologically clean GHRH receptor agonist with documented in vivo stability. Research applications include GH pulse characterization, GH-axis-mediated lipolysis, IGF-1 regulation in metabolic models, and comparison with shorter-acting GHRH analogs in dose-response protocols.
Common questions
You might also want to check out these products.
2X Blend CJC-1295 Without DAC / Ipamorelin
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
CJC-1295 With DAC
$25.00
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
GHRP-6 Acetate
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
Ipamorelin
$12.00
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
IGF-1LR3
$30.00
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
MOD GRF 1-29
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
GHRP-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy